AI Scan Can Detect Parkinson’s Before Symptoms Appear

A groundbreaking development in medical science has emerged, with scientists introducing eye scans empowered by artificial intelligence to identify early indicators of Parkinson’s disease up to seven years before any noticeable symptoms surface. This groundbreaking advancement marks the first instance where the condition can be detected well in advance of an official diagnosis.

Parkinson’s disease, a progressive neurological disorder characterized by a reduction in dopamine, has long posed challenges for early detection. However, a recent study published in the Neurology journal on Tuesday has showcased promising results. Leveraging two extensive pools of health data, the AlzEye dataset and the UK Biobank database, the research succeeded in pinpointing subtle markers of Parkinson’s, despite the condition’s relatively low prevalence within this demographic.

The AlzEye dataset, a compilation of retinal images and accompanying clinical data, was harnessed from the world’s largest repository of such images. Remarkably, post-mortem examinations of individuals afflicted by Parkinson’s have revealed discrepancies in the inner nuclear layer (INL) of the retina.

What is particularly intriguing is that this study builds upon prior research that has unveiled the potential of eye scans in identifying early signs of various neurological conditions like Alzheimer’s, multiple sclerosis, and schizophrenia. This expanding realm of study, termed “oculomics,” explores the use of eye scan data to offer insights into not just neurological ailments, but also conditions such as high blood pressure, heart disease, stroke, and diabetes.

Traditionally, medical practitioners have relied on physical eye examinations, recognizing the eye as a “window” into the broader spectrum of human health. Now, armed with high-resolution retinal images as a standard aspect of eye care, researchers emphasize the enhanced analytical capabilities to glean more profound insights into patient well-being.

Of specific note is a type of three-dimensional scan called optical coherence tomography (OCT), commonly employed in eye clinics and by optometrists. OCT scans provide intricate cross-sections of the retina—a mesh of nerves at the back of the eye—with astonishing precision down to the thousandth of a millimeter. These retinal images serve as valuable tools for monitoring ocular health. However, researchers are uncovering their potential to be more transformative, as they are the only non-invasive means to observe subcutaneous cell layers.

Remarkably, a reduced thickness in these cell layers was linked to an elevated likelihood of developing Parkinson’s disease. Moreover, scientists are harnessing the potency of robust computers and AI technology to swiftly scrutinize a multitude of OCTs and other eye images—a process that would take a human significantly longer.

Siegfried Wagner, co-author of the study from University College London, shared the team’s aspirations for the future, expressing that while predicting individual Parkinson’s development remains a goal for the future, the method could evolve into a pre-screening tool for those at risk. This could potentially allow for timely lifestyle adjustments to stave off certain conditions and enable clinicians to delay the onset and impact of debilitating neurodegenerative disorders.

Researchers highlight that the employed OCT technique is not only non-invasive and more cost-effective, but it’s also more scalable and expedient compared to brain scans for this particular purpose. This monumental leap forward in medical technology could revolutionize early disease detection and usher in a new era of proactive healthcare management.


Become a member – follow the lead of experienced investors. Sign Up